Wei Ding Profile
Wei Ding

@WeiDing3

Followers
369
Following
941
Media
8
Statuses
143

Hematologist, cancer researcher, Mayo clinic, Rochester

Minnesota, USA
Joined December 2013
Don't wanna be here? Send us removal request.
@LiliWangLab
Lili Wang Lab
2 years
@PrajishIyer will also be presenting a poster on identification of T cell subsets using single-cell sequencing that predict chemo sensitivity in RT. This work was done in collaboration with @WeiDing3 and others @MayoClinic! #ASH23 #lymphoma https://t.co/yCKv8hpaxl
1
2
4
@WeiDing3
Wei Ding
2 years
The most important CLL study present at ASCO this year. Caution for triplets therapy.
@ASCOPost
The ASCO Post
2 years
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax https://t.co/tmZpdoozS3 #leusm #leukemia #COVID19 #hematology #ASCO23 @OSUCCC_James
0
0
5
@WeiDing3
Wei Ding
3 years
Glad we got this open
@YucaiWangMD
Yucai Wang, MD, PhD
3 years
MIRACLE, an investigator-initiated study of MRD-guided, time-limited frontline therapy with pirtobrutinib and venetoclax for CLL/SLL, sponsored by @LoxoLillyOnc, is now open @MayoCancerCare. https://t.co/v39xNZxi3H
0
0
2
@LiliWangLab
Lili Wang Lab
3 years
Happy Chinese Year of the Rabbit! Looking forward to a wonderful new year of research and fantastic new discoveries.
0
2
13
@WeiDing3
Wei Ding
4 years
Wonderful presidential symposium, thanks for putting it together!#ASH21
@ASH_hematology
ASH
4 years
#ASHKudos to 2021 ASH President @MartinTallman!
0
0
3
@WeiDing3
Wei Ding
4 years
Congrats for Steve’s outstanding contribution for clinical translational discovery using PD-1 antibody to treat Hodgkin lymphoma- Ernst Beutler award!
@YiLinMDPhD
Yi Lin
4 years
Congratulations to Dr. Stephen Ansell for being awarded the Ernst Beutler Prize for his clinical and translational work on PD-1 in Hodgkin lymphoma #ASH21 @MayoCancerCare
0
1
5
@WeiDing3
Wei Ding
4 years
Congrats for our senior fellow Dr. Hampel’s wonderful presentation!
@hampel_p
Paul Hampel
4 years
Great day 2 at #iwCLL2021 and thankful for the opportunity to present our study on post ibrutinib progression outcomes. Incredible (virtual) international gathering of people dedicated to improving care of patients w/ CLL @sparikhmd @WeiDing3 @neilkay15 @kenderian_ss @hemepa_c
0
0
4
@WeiDing3
Wei Ding
4 years
Wonderful work by mayo cell colleagues!@sparikhmd @kenderian_ss @neilkay15
@BloodPortfolio
Blood Journals Portfolio
4 years
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL https://t.co/6gOr0XGATv
0
0
1
@WeiDing3
Wei Ding
5 years
Glad to see mayo clinic celebrate international women’s day with our successful mayo women physician and scientists!
@MayoClinicCIM
Mayo Clinic Center for Individualized Medicine
5 years
In honor of International Womens Day on March 8, meet eight (of many) trailblazing women in Mayo Clinic's Center for Individualized Medicine: https://t.co/JqRWExboUE #IWD2021 #ChooseToChallenge
0
0
4
@WeiDing3
Wei Ding
5 years
Ox typically implicates strong move and finish, let us hope this is a positive and recover year!
@LiliWangLab
Lili Wang Lab
5 years
新年快乐! Happy year of the Ox!
1
0
5
@WeiDing3
Wei Ding
5 years
The vaccine wars!
@ScienceMagazine
Science Magazine
5 years
As #vaccines for #covid19 are distributed all across the globe, we look back at this data visualization from 2017 that illustrates the power of vaccines to vanquish disease—an impact that far eclipses their minute risks. 👉 https://t.co/sFPgOS3imm
0
0
3
@WeiDing3
Wei Ding
5 years
Excellent presentation and work by Dr. Phase Benjamini, CART for RT, 6/9 CR for heavily double refractory CLL to RT patients. Still relapses after CR to CART. But good intermediate for allo?
0
0
3
@WeiDing3
Wei Ding
5 years
Exciting new therapy option, excellent talk.
@NitinJainMD
Nitin Jain
5 years
Excellent data presentation by @anthonymatomd on LOXO-305 in CLL. Congratulations!!
0
0
3
@WeiDing3
Wei Ding
5 years
Amazing result for bispecific. @sparikhmd possible good option for RT.
@WeiDing3
Wei Ding
5 years
@YucaiWangMD Particularly amazed with this SubQ option.
1
0
2
@WeiDing3
Wei Ding
5 years
Glad to see the collaboration for novel combination using the idea of novel synthetic lethality nicely presented by Dr. Mato @anthonymatomd
@YucaiWangMD
Yucai Wang, MD, PhD
5 years
DTRM-555, synthetic lethality based BTKi/mTORi/IMiD triplet pill, promising activity in heavily pretreated Richter and de novo DLBCL. Ph2 ongoing. @anthonymatomd @WeiDing3 @DtrmWeihe
0
1
2
@LiliWangLab
Lili Wang Lab
5 years
Prajish's work in collaboration with @WeiDing3 and @MayoClinic has been very fruitful. This finding may hopefully lead to additional studies on Treg functions and inform future clinical decisions with regards to immune checkpoint inhibitors.
0
3
8
@WeiDing3
Wei Ding
5 years
I am very glad that we collaborate on this project and congrats for excellent work @LiliWangLab @PrajishIyer
@LiliWangLab
Lili Wang Lab
5 years
I am excited to announce that @PrajishIyer from my lab has won the ASH Abstract Achievement Award. Prajish worked very hard on this project with @WeiDing3 and @MayoClinic. I could not be more proud of him. #ASH20 #hematology #Lymphoma
1
0
2
@WeiDing3
Wei Ding
5 years
Indeed excellent review of CLL in NEJM
@hemepa_c
Amber Koehler, PA-C
5 years
Great to see not just one, but two articles on CLL in today's @NEJM ! 1. Review of Treatment in CLL: https://t.co/q3QWHeMZwW 2. Longer term follow-up of ibrutinib in patients with TP53 alterations in CLL:
0
0
5
@WeiDing3
Wei Ding
5 years
Indeed super cool!
@XShirleyLiu
Xiaole Shirley Liu
5 years
Check out https://t.co/wtCEP4eHcw for uniformly processed and annotated tumor @scRNAseq data of > 2M cells! Very nice visualization and user-friendly features.
0
0
1
@WeiDing3
Wei Ding
6 years
What would you do?
@sparikhmd
Sameer Parikh
6 years
72 yo asymptomatic male with previously untreated Rai IV CLL to begin single-agent BTKi therapy. Prior to starting BTKi, which of the following tests will you do? @NitinJainMD @anthonymatomd @DrMDavids @mshadman @kenderian_ss @WeiDing3 @neilkay15
0
0
1